iOnctura commences randomized Phase II study in metastatic uveal melanoma

First patient dosed in Phase II OCULE-01 study with roginolisib, an allosteric modulator of PI3Kδ The European Medicines Agency (EMA) has granted Orphan Drug Designation for roginolisib for treatment of uveal melanoma – benefits include 10 years market exclusivity in the European Union…